TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29923931

Group type: EXPERIMENTAL
Intervention: Hypertonic lactate (sodium lactate, 1,000 mmol/L; concentration, 30 µmol/kg/min) administered via three-hour IV infusion 39 hours from injury.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study: 29923998

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 620

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 620
Study: 29924294

Group type: EXPERIMENTAL
Intervention: High-fat labeled yogurt (10% fat)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-fat labeled yogurt (0.1% fat)
Number of subjects: 26
Study: 29924298

Group type: EXPERIMENTAL
Intervention: Modified Healthy Lifestyle Index (HLI) variables and metabolic signatures
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Metabolomic profile
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Lifestyle component's PLS score
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Metabolites sphingomyelin (SM) (OH) C14:1, C16:1, C22:2
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Glutamate, hexoses, diacyl-phosphatidylcholine PC aaC32:1
Number of subjects: 294
Study: 29924320

Group type: EXPERIMENTAL
Intervention: Serum retinol
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Height-for-age z score
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Weight-for-age z score
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Soluble transferrin receptor
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 542
Study: 29925332

Group type: EXPERIMENTAL
Intervention: Continuing medical education (CME) meeting, a four-hour educational meeting performed by GPs and specialists in palliative care.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electronic decision support (EDS), integrated into existing electronic records.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall intervention (CME and EDS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CME meetings
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EDS
Number of subjects: 120
Study: 29925376

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (hydrochlorothiazide and chlorthalidone)
Number of subjects: 150
Study: 29925397

Group type: EXPERIMENTAL
Intervention: Low-SAR imaging with nitinol guidewire (150 cm × 0.035" Terumo Glidewire)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard catheterization without guidewire
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-SAR imaging with nitinol guidewire
Number of subjects: 7
Study: 29925433

Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 29

Group type: COMPARATOR
Intervention: Mipomersen
Number of subjects: 29

Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 29
Study: 29925491

Group type: EXPERIMENTAL
Intervention: Mobile app and accelerometer intervention (2 intervention groups: Regular and Plus)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Weight Loss group (n=19)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Illness Prevention group (n=138)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Health Promotion group (n=46)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity activity level among the 3 groups
Number of subjects: 203
Study: 29925497

Group type: EXPERIMENTAL
Intervention: CCAT (computerized cognitive addiction therapy) for 4 weeks plus regular detoxification treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular detoxification treatment as usual
Number of subjects: 40
Study: 29925496

Group type: EXPERIMENTAL
Intervention: Habit app intervention
Number of subjects: 39
Study: 29925499

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-modified T cells targeting CD19
Number of subjects: 0
Study: 29925549

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA) use
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA) discontinuation
Number of subjects: 411
Study: 29925553

Group type: EXPERIMENTAL
Intervention: Pasireotide (Signifor; Signifor LAR)
Number of subjects: 1
Study: 29925913

Group type: EXPERIMENTAL
Intervention: Concomitant 5-ASA
Number of subjects: 2183
Study: 29926156

Group type: EXPERIMENTAL
Intervention: Defined subclones (1 to 3 subclones)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Composite karyotypes (CP)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Defined subclones
Number of subjects: 1291
Study: 29926288

Group type: EXPERIMENTAL
Intervention: Sedation in critically ill patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Blood sampling at 12-hour intervals over a 5-day period
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time from eligibility to enrolment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time from eligibility to the first blood sample
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation of plasma noradrenaline levels with norepinephrine dose
Number of subjects: 12
Study: 29926400

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg/day for 20 weeks, then 50 or 100 mg/day for 32 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg/day (for patients with insufficient control on 50 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ipragliflozin and GLP-1 receptor agonists/sulfonylureas
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 103
Study: 29926826

Group type: EXPERIMENTAL
Intervention: INET (intra-neuroendoscopic technique)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (extraventricular drainage plus urokinase thrombolytic therapy)
Number of subjects: 65
Study: 29926892

Group type: EXPERIMENTAL
Intervention: Laryngeal handshake method
Number of subjects: 123

Group type: COMPARATOR
Intervention: Simple palpation
Number of subjects: 123
Study: 29927663

Group type: EXPERIMENTAL
Intervention: Accu-Chek
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All five systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lay-users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study personnel
Number of subjects: 0
Study: 29927704

Group type: EXPERIMENTAL
Intervention: 15 µg plague vaccine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 30 µg plague vaccine
Number of subjects: 240
Study: 29927782

Group type: EXPERIMENTAL
Intervention: Early-treatment group (15 months or less from diagnosis to cryoablation)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Late-treatment group (greater than 15 months from diagnosis to cryoablation)
Number of subjects: 510
Study: 29927832

Group type: COMPARATOR
Intervention: Immediate DIEP flap reconstruction without postmastectomy radiotherapy
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Immediate DIEP flap reconstruction with postmastectomy radiotherapy
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Delayed reconstruction after simple mastectomy
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mastectomy with temporizing implant, postmastectomy radiotherapy, and DIEP flap reconstruction
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Immediate DIEP flap reconstruction or mastectomy with temporizing implant then DIEP flap surgery
Number of subjects: 167
Study: 29928759

Group type: EXPERIMENTAL
Intervention: SST algorithm in Japanese patients
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: SST algorithm in Japanese patients after propensity score matching
Number of subjects: 181

Group type: COMPARATOR
Intervention: SST algorithm in other geographies (OJPN)
Number of subjects: 181
Study: 29929047

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to phenylurea herbicide isoproturon
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to phenoxyherbicide 2-methyl-4-chlorophenoxyacetic acid
Number of subjects: 25
Study: 29929092

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin (60 mg/m²) and ifosfamide for six cycles
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin and ifosfamide
Number of subjects: 150
Study: 29929491

Group type: EXPERIMENTAL
Intervention: Chloroquine (NET inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (part of preoperative chemotherapy)
Number of subjects: 0
Study: 29929493

Group type: EXPERIMENTAL
Intervention: self-hypnosis/self-care group intervention
Number of subjects: 93
Study: 29929514

Group type: EXPERIMENTAL
Intervention: Fluorescent Spot Test (FST)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: RDT compared to FST
Number of subjects: 1262
Study: 29930021

Group type: COMPARATOR
Intervention: Clopidogrel (standard regimen)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (T90)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg (T60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ticagrelor (T60 or T90)
Number of subjects: 180
Study: 29930943

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 77

Group type: COMPARATOR
Intervention: Copeptin
Number of subjects: 77

Group type: COMPARATOR
Intervention: hs-cTnT
Number of subjects: 77
Study: 29931040

Group type: EXPERIMENTAL
Intervention: Chocolate intake <1/mo
Number of subjects: 83310

Group type: EXPERIMENTAL
Intervention: Chocolate intake 1 to <1.5/mo
Number of subjects: 83310

Group type: EXPERIMENTAL
Intervention: Chocolate intake 1.5 to <3.5/mo
Number of subjects: 83310

Group type: EXPERIMENTAL
Intervention: Chocolate intake 3.5/mo to <3/wk
Number of subjects: 83310

Group type: EXPERIMENTAL
Intervention: Chocolate intake ≥3/wk
Number of subjects: 83310

Group type: EXPERIMENTAL
Intervention: Chocolate intake (combined for age <65 y)
Number of subjects: 83310

Group type: COMPARATOR
Intervention: Chocolate intake and risk of CHD
Number of subjects: 83310

Group type: COMPARATOR
Intervention: Chocolate intake and risk of stroke
Number of subjects: 83310

Group type: COMPARATOR
Intervention: Chocolate intake and risk of CHD and stroke combined
Number of subjects: 83310

Group type: EXPERIMENTAL
Intervention: Age modification effect
Number of subjects: 83310
Study: 29931068

Group type: EXPERIMENTAL
Intervention: 25-Hydroxyvitamin D deficiency (<20 ng/mL)
Number of subjects: 6302

Group type: COMPARATOR
Intervention: 25-Hydroxyvitamin D replete (≥30 ng/mL)
Number of subjects: 6302
Study: 29931248

Group type: EXPERIMENTAL
Intervention: Profile 3D annuloplasty ring
Number of subjects: 148
Study: 29931424

Group type: EXPERIMENTAL
Intervention: 72-hour fasting
Number of subjects: 0
Study: 29931453

Group type: EXPERIMENTAL
Intervention: Thalidomide 50 mg qn for 3 months
Number of subjects: 0
Study: 29931812

Group type: EXPERIMENTAL
Intervention: Postprandial triglycerides (PPTGs) measured at 1-hour and 2-hour after a controlled liquid breakfast
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fasting triglycerides (TGs)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Increase in TGs from early to later pregnancy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Maternal glucose
Number of subjects: 54
Study: 29932498

Group type: EXPERIMENTAL
Intervention: Structured light plethysmography (SLP) before bronchodilator treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Structured light plethysmography (SLP) after bronchodilator treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Structured light plethysmography (SLP) in healthy children
Number of subjects: 39
Study: 29933073

Group type: EXPERIMENTAL
Intervention: CC-486 (200 mg, n=3; 300 mg, n=4) once daily for 7 days per cycle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CC-486 (150 mg, n=4; 200 mg, n=19) for 14 days per cycle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CC-486 maintenance therapy
Number of subjects: 30
Study: 29933095

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally, twice daily) combined with gemcitabine (1000 mg/m2) and cisplatin chemotherapy
Number of subjects: 26
Study: 29933096

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg once daily
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 1298
Study: 29933267

Group type: EXPERIMENTAL
Intervention: GA + neuraxial anesthesia
Number of subjects: 9442

Group type: COMPARATOR
Intervention: GA only
Number of subjects: 9442

Group type: EXPERIMENTAL
Intervention: Blood transfusions
Number of subjects: 9442

Group type: EXPERIMENTAL
Intervention: Surgery in a rural hospital
Number of subjects: 9442
Study: 29933272

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at target plasma concentrations of 0.3, 0.6, 1.2, and 2.4 ng/mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 16
Study: 29933761

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by minimally-invasive robotic surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BH3 profiling and metabolomics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard evaluation including CT scans, laboratory tests, endoscopy with biopsies
Number of subjects: 0
Study: 29933912

Group type: EXPERIMENTAL
Intervention: Post-transplantation (xdcfDNA percentage)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Post-transplantation (xdcfDNA levels)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Elevations in xdcfDNA percentage
Number of subjects: 7
Study: 29934373

Group type: EXPERIMENTAL
Intervention: ACR/EULAR Boolean remission (44 joints)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ultrasound power Doppler remission
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ultrasound grey scale remission
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Clinical remission criteria
Number of subjects: 103

Group type: COMPARATOR
Intervention: No remission criteria
Number of subjects: 103
Study: 29934383

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1000
Study: 29934393

Group type: EXPERIMENTAL
Intervention: Haemoperfusion (HP)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Concurrent HP-HD
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All groups (HP, HD, concurrent HP-HD, Control)
Number of subjects: 360
Study: 29934394

Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 29934395

Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Hydromorphone (HM)
Number of subjects: 400
Study: 29934438

Group type: EXPERIMENTAL
Intervention: LTA agonist and native LGG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LGG with a mutation in the processing of lipoteichoic acid (LTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LGG given by gavage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clodronate liposomes (macrophage depletion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LTA in fractionated radiation regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXCR4 agonist
Number of subjects: 0
Study: 29934842

Group type: EXPERIMENTAL
Intervention: Permanent Iodine-125 Seed Implantation, median biologically effective dose (BED) about 180 Gy
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: Permanent Iodine-125 Seed Implantation
Number of subjects: 2316
Study: 29934885

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance imaging (CMR) assessment of pulmonary artery (PA) stiffness, measuring pulsatility, distensibility, compliance, and capacitance.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal controls (n=18)
Number of subjects: 51
Study: 29935107

Group type: EXPERIMENTAL
Intervention: Dietary α-linolenic acid (ALA) intake
Number of subjects: 15100

Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid (LA) intake
Number of subjects: 15100

Group type: EXPERIMENTAL
Intervention: LA- or ALA-enriched high-fat diet (HFD) in DIO mice
Number of subjects: 15100
Study: 29935143

Group type: EXPERIMENTAL
Intervention: Early capsule endoscopy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 87
Study: 29935153

Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback (VTF) in a dark room
Number of subjects: 12

Group type: COMPARATOR
Intervention: No vibrotactile feedback (Control) in a dark room
Number of subjects: 12
Study: 29935381

Group type: EXPERIMENTAL
Intervention: East/South East Asian ethnicity
Number of subjects: 1594
Study: 29935441

Group type: EXPERIMENTAL
Intervention: Increased cognitive control through neural recruitment during the affective stroop task (fMRI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Increased BOLD response over time to emotional relative to neutral stimuli in inferior parietal cortex
Number of subjects: 21

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study: 29935581

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 47
Study: 29935596

Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 31024

Group type: EXPERIMENTAL
Intervention: Supraglottic airway insertion
Number of subjects: 31024

Group type: EXPERIMENTAL
Intervention: Difficult airway management
Number of subjects: 31024
Study: 29935810

Group type: EXPERIMENTAL
Intervention: Endometrioma group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Endometrioma group (AFC)
Number of subjects: 80
Study: 29936063

Group type: EXPERIMENTAL
Intervention: IMAB362 (Zolbetuximab) 33, 100, 300, 600, and 1000 mg/m2 single dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IMAB362 (Zolbetuximab) 600 mg/m2 single dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IMAB362 (Zolbetuximab)
Number of subjects: 15
Study: 29936064

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 120 mg/m²
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 240 mg/m²
Number of subjects: 64
Study: 29936086

Group type: COMPARATOR
Intervention: Prior diabetes treatment assignment
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Glycemic control over time
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Age, race-ethnicity, sex, higher blood pressure and BMI
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Targeting blood pressure and obesity
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Arterial stiffness measurement
Number of subjects: 453
Study: 29936327

Group type: EXPERIMENTAL
Intervention: Continuous electronic cardiorespiratory monitoring (CEM) using pulse oximetry and capnography
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Continuous electronic cardiorespiratory monitoring (CEM)
Number of subjects: 1650
Study: 29936438

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNFi monotherapy
Number of subjects: 0
Study: 29936535

Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - everyday consumption
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - every other day
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - 1-2 times a week
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Teff injera consumption (TI) - once in 2 weeks
Number of subjects: 592
Study: 29937300

Group type: EXPERIMENTAL
Intervention: FFR-guided revascularisation deferral
Number of subjects: 292
Study: 29937325

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 336
Study: 29937365

Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE)
Number of subjects: 10
Study: 29938395

Group type: EXPERIMENTAL
Intervention: Everolimus (E), Trastuzumab (T), and Vinorelbine (V)
Number of subjects: 32
Study: 29938772

Group type: EXPERIMENTAL
Intervention: Twice-weekly ixazomib 3·0 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Twice-weekly ixazomib-Rd
Number of subjects: 64
Study: 29938825

Group type: EXPERIMENTAL
Intervention: Cord blood insulin
Number of subjects: 162

Group type: COMPARATOR
Intervention: Maternal metabolic indices
Number of subjects: 162
Study: 29939053

Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Family-Enhanced Nondirective Supportive Therapy (FE-NST)
Number of subjects: 129
Study: 29939981

Group type: EXPERIMENTAL
Intervention: Motion-based attention task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color-based attention task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effective connectivity analysis using DCM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effective connectivity analysis using GCM
Number of subjects: 0
Study: 29940167

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis implantation
Number of subjects: 33
Study: 29940251

Group type: EXPERIMENTAL
Intervention: Transperineal template prostate mapping biopsy
Number of subjects: 249
Study: 29940782

Group type: EXPERIMENTAL
Intervention: Stimulant medication (single dose)
Number of subjects: 87
Study: 29940870

Group type: EXPERIMENTAL
Intervention: Inpatients with unipolar major depression
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 82
Study: 29940894

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Replacing 30 min of sedentary time with 30 min of MVPA
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Light-intensity activity
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Replacing sedentary time with light-intensity activity
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Replacing light activity with MVPA
Number of subjects: 271